Velcade-melphalan association as conditioning regimen before autologous stem-cell transplantation in multiple myeloma patients under 65 years.

Trial Profile

Velcade-melphalan association as conditioning regimen before autologous stem-cell transplantation in multiple myeloma patients under 65 years.

Completed
Phase of Trial: Phase II

Latest Information Update: 15 May 2017

At a glance

  • Drugs Bortezomib (Primary) ; Melphalan (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Oct 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 11 Oct 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top